Abate As Industries Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Abate As Industries Ltd filed with BSE on 04 Jun 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Abate AS Industries reported consolidated revenue of approximately Rs.161.68 Crores for FY2026, up about 67% year-on-year, with profit after tax rising to approximately Rs.12.3 Crores from Rs.1.1 Crores in FY2025. The company generated positive operating cash flow of approximately Rs.6.1 Crores during the year, compared to negative operating cash flow in FY2025. Management described healthcare as its primary long-term growth driver, contributing about 22% of consolidated revenue, alongside retail, education, and Bahrain operations.
Numbers mentioned
Consolidated revenue: approximately Rs.160 Crores (FY2026)
p. 3
“the company delivered consolidated revenue of approximately Rs.160 Crores, representing growth of nearly 67% over FY2025”
Dr. A. Samsudheen, page 3 of the filed PDF · View the filing
Consolidated revenue: Rs.161.68 Crores (FY2026)
p. 4
“Rs.161.68 Crores consolidated revenue 67% year-on-year”
George C. Chacko, page 4 of the filed PDF · View the filing
Profit after tax: approximately Rs.12.3 Crores (FY2026)
p. 3
“profit after tax increased to approximately Rs.12.3 Crores from Rs.1.1 Crores in the previous year”
Dr. A. Samsudheen, page 3 of the filed PDF · View the filing
Operating cash flow: approximately Rs.6.1 Crores (FY2026)
p. 4
“Rs.6.1 Crores operating cash flow positive percent”
George C. Chacko, page 4 of the filed PDF · View the filing
Cash and equivalents: approximately Rs.3.5 Crores (FY2026)
p. 5
“cash equivalent increased to approximately Rs.3.5 Crores, while net worth increased to approximately Rs.199 Crores”
George C. Chacko, page 5 of the filed PDF · View the filing
Net worth: approximately Rs.199 Crores (FY2026)
p. 5
“cash equivalent increased to approximately Rs.3.5 Crores, while net worth increased to approximately Rs.199 Crores”
George C. Chacko, page 5 of the filed PDF · View the filing
Healthcare revenue contribution: 22% (FY2026)
p. 6
“Healthcare currently contributes approximately 22% of consolidated revenue, but its strategic significance extends far beyond its current revenue share”
Dr. A. Samsudheen, page 6 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Healthcare revenue mix — 70% to 80%
stated as an aspiration by Dr. A. Samsudheen
p. 6
“Our strategic objective is to progressively increase healthcare contribution to both revenue and profitability over time.”
Dr. A. Samsudheen, page 6 of the filed PDF · View the filing
EBITDA margin — 18% to 20% · 2026, 2027, 2028, 2029
stated as an aspiration by George C. Chacko
p. 7
“We are targeting to maintain around 18% to 20% overall, the profitability of EBITDA in the coming years 2026, 2027, and 2028, 2029.”
George C. Chacko, page 7 of the filed PDF · View the filing
Capital expenditure — around 50 crore
stated conditionally by Dr. A. Samsudheen
p. 6
“management estimates around 50 crore capital could be required to support future expansions, however the management is still evaluating its alternatives as of now.”
Dr. A. Samsudheen, page 6 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said healthcare's strategic significance extends beyond its current 22% revenue share due to higher margins and growth potential, and reiterated the objective to progressively increase healthcare's contribution over time without giving specific yearly targets.
Answered by Dr. A. Samsudheen
Asked by Vivek Bersa: What healthcare revenue mix should investors expect in FY2027 and FY2028 given the long-term target of 70-80%?
p. 6
“Healthcare operates at structurally higher margins than retail, benefits from operating leverage, and offers significantly larger long-term growth opportunity.”
Dr. A. Samsudheen, page 6 of the filed PDF · View the filing
Management said capital priority is strengthening the healthcare platform and evaluating selective acquisitions, while remaining disciplined on capital allocation.
Answered by Dr. A. Samsudheen
Asked by Vivek Bersa: What will be the segment-wise capex in FY2027?
p. 6
“Our first priority is to invest in the opportunity that strengthens the healthcare platform, expanding capital capacity, improving utilization across the existing facilities, enhancing clinical capability, and investing in technology and infrastructure where appropriate.”
Dr. A. Samsudheen, page 6 of the filed PDF · View the filing
Management estimated around Rs 50 crore of capital could be needed for future expansion but said funding alternatives are still being evaluated.
Answered by Dr. A. Samsudheen
Asked by Vivek Bersa: What are the expected capex numbers and how will they be funded?
p. 6
“As we look ahead, management estimates around 50 crore capital could be required to support future expansions, however the management is still evaluating its alternatives as of now.”
Dr. A. Samsudheen, page 6 of the filed PDF · View the filing
Management pointed to growth in patient volumes, procedures and utilization across healthcare facilities, and said it sees further opportunities through new clinics, specialty expansion, international patients, and acquisitions.
Answered by Dr. A. Samsudheen
Asked by Shivam Kabra: What gives management confidence that the growth trajectory can continue over the next few years?
p. 7
“We also see opportunities through additional clinics, expansion of specialty services, international patient growth, and selective acquisitions.”
Dr. A. Samsudheen, page 7 of the filed PDF · View the filing
The CFO compared the hospital segment's current operating profit to listed peers and stated a target EBITDA margin range for coming years.
Answered by George C. Chacko
Asked by Nikhil Kumar: What margin target should investors accept over the medium term?
p. 7
“We are targeting to maintain around 18% to 20% overall, the profitability of EBITDA in the coming years 2026, 2027, and 2028, 2029.”
George C. Chacko, page 7 of the filed PDF · View the filing
Management called it one of the most important achievements of FY2026, showing growth is translating into real cash generation, and said it intends to keep improving cash conversion and working capital efficiency.
Answered by Dr. A. Samsudheen
Asked by Navin Ravindra: How significant is the positive operating cash flow of Rs.6.1 Crores and what does it mean going forward?
p. 8
“the management views positive operating cash flow as one of the most important achievements of FY2026”
Dr. A. Samsudheen, page 8 of the filed PDF · View the filing
Risks flagged
Trade receivables increased as healthcare platform scaled, influenced by TPA and institutional settlement cycles
p. 5
“Trade receivable increased during the year as healthcare platform continued to scale, while healthcare receivables are naturally influenced by TPA and institutional settlement cycles.”
George C. Chacko, page 5 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.